N-benzyl-1H-indazole-3-carboxamide | 101101-71-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-benzyl-1H-indazole-3-carboxamide
• CAS: 101101-71-7；923845-85-6
• 化学式: C₁₅H₁₃N₃O
• 分子量: 251.288
• InChiKey: DRHKBMTWDVYDPG-UHFFFAOYSA-N

物化性质

• 沸点：
  568.1±33.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲唑-3-羧酸 、 苄胺 在 硼酸三(2,2,2-三氟乙基)酯 作用下， 125.0 ℃ 、101.33 kPa 条件下， 反应 24.0h， 以79%的产率得到N-benzyl-1H-indazole-3-carboxamide
  参考文献：
  名称：

  B(OCH₂CF₃)₃-mediated direct amidation of pharmaceutically relevant building blocks in cyclopentyl methyl ether

  摘要：

  在环戊基甲醚（CPME）中，使用B(OCH2CF3)3直接对具有药用相关性的羧酸和胺进行酰胺化反应。

  DOI：

  10.1039/c5ob01801c

文献信息

• Synthesis of 3-Indazolecarboxylic Esters and Amides via Pd-Catalyzed Carbonylation of 3-Iodoindazoles
  作者：Hans-Peter Buchstaller、Kai Wilkinson、Kasimir Burek、Yasmin Nisar

  DOI：10.1055/s-0030-1260199

  日期：2011.10

  A straightforward and effective procedure for the preparation of 1H-indazole-3-carboxylic acid esters and amides was developed. A series of functionalized 3-iodoindazoles were subjected to Pd-catalyzed carbonylations in the presence of methanol or amines, yielding the title compounds in moderate to good yield. For the majority of examples, the reaction proceeded cleanly under mild conditions, which

  开发了一种简单有效的制备1 H-吲哚-3-羧酸酯和酰胺的方法。在甲醇或胺的存在下，对一系列官能化的3-碘吲唑进行Pd催化的羰基化反应，以中等至良好的收率得到标题化合物。对于大多数实例，反应在温和条件下干净地进行，该条件易于被允许进一步合成转化的多种官能团所耐受。 羰基化-酯-酰胺-烷氧基羰基化-氨基羰基化-碘吲唑-钯催化
• INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA
  申请人：D'ORCHYMONT Hugues

  公开号：US20070185187A1

  公开（公告）日：2007-08-09

  The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.

  该发明涉及治疗或预防疟疾的方法，包括向需要的患者施用一种通式（I）的1H-吲唑-3-羧酰胺衍生物的有效量，其为碱式或与酸形成的加合盐的形式，或为所述碱式或酸性加合盐的水合物或溶剂化合物的形式。
• CANNABINOID RECEPTOR MODULATORS, THEIR PROCESSES OF PREPARATION, AND USE OF CANNABINOID RECEPTOR MODULATORS FOR TREATING RESPIRATORY AND NON-RESPIRATORY DISEASES
  申请人：Bristol-Myers Squibb Co.

  公开号：EP1254115A2

  公开（公告）日：2002-11-06
• G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
  申请人：Bagnol Didier

  公开号：US20110038850A1

  公开（公告）日：2011-02-17

  The present invention relates to methods of using BRS-3 to screen candidate compounds as compounds suitable for the treatment of sleep-related disorders. Inverse agonists and antagonists of the invention are useful as therapeutic agents for promoting sleep and for preventing or treating sleep disorders ameliorated by promoting sleep, such as insomnia and the like. Agonists and partial agonists of the invention are useful as therapeutic agents for promoting wakefulness and for preventing or treating excessive sleepiness, such as excessive sleepiness associated with narcolepsy and the like. The invention further relates to methods of using a BRS-3 to screen candidate compounds as pharmaceutical agents for a GABA-related neurological disorder such as a sleep disorder, an anxiety disorder, a convulsive disorder, migraine, a depressive disorder, a psychotic disorder, or a cognitive disorder. Compounds of the invention encompass compounds having sleep-promoting, wakefulness-promoting, anxiolytic, anticonvulsant, antidepressant, antipsychotic, and cognition-enhancing activities.
• US7842711B2
  申请人：——

  公开号：US7842711B2

  公开（公告）日：2010-11-30